Evidence map›Paper›PMID 42355983›Full record

ArticleJournal of clinical medicine2026

Enzalutamide Versus Abiraterone After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Real-World Outcomes and Exploratory Prognostic Stratification.

Mert Tohumcuoğlu, Tolga Köşeci, Alpay Düşgün, Abdullah Evren Yetişir, Cem Mirili, Burak Mete, Mahmut Büyükşimşek

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mert TohumcuoğluDepartment of Medical Oncology, Adana City Training and Research Hospital, University of Health Sciences, Adana 01230, Türkiye.ORCID 0000-0003-3653-4429
Tolga KöşeciDepartment of Medical Oncology, Faculty of Medicine, Çukurova University, Adana 01330, Türkiye.
Alpay DüşgünDepartment of Medical Oncology, Adana City Training and Research Hospital, University of Health Sciences, Adana 01230, Türkiye.ORCID 0000-0003-2994-9191
Abdullah Evren YetişirDepartment of Medical Oncology, Adana City Training and Research Hospital, University of Health Sciences, Adana 01230, Türkiye.
Cem MiriliMedical Oncology Clinic, Adana Ortadoğu Hospital, Adana 01140, Türkiye.ORCID 0000-0002-5986-5493
Burak MeteDepartment of Public Health, Faculty of Medicine, Çukurova University, Adana 01330, Türkiye.ORCID 0000-0002-0780-6176
Mahmut BüyükşimşekDepartment of Medical Oncology, Adana City Training and Research Hospital, University of Health Sciences, Adana 01230, Türkiye.ORCID 0000-0001-6356-9059

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

abiraterone acetatedocetaxelenzalutamidemetastatic castration-resistant prostate cancernomogramoverall survivalpan-immune-inflammation valueprognostic score

Identifiers

PMID42355983
PMCPMC13300754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.